SCHEMBL753188

SCHEMBL753188

C[C@H](c1ccc(C(=O)Nc2cccc(C(=O)O)n2)cc1Cl)[C@@](O)(c1ccnc(Cl)c1)C(F)(F)F

nearest known ligand 0.37

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
SMN1; SMN2 Q16637 2/20 0.36
KDM4E B2RXH2 1/20 0.36
LMNA P02545 1/20 0.36
ALDH1A1 P00352 1/20 0.36
GRM5 P41594 1/20 0.36
KMT2A Q03164 1/20 0.36
HTR1F P30939 1/20 0.35
BTK Q06187 3/20 0.35
NPC1 O15118 2/20 0.35
TP53 P04637 1/20 0.35
MAPT P10636 1/20 0.35
MAP3K5 Q99683 2/20 0.35
RXFP1 Q9HBX9 1/20 0.35
NFKB1 P19838 1/20 0.35
RAB9A P51151 1/20 0.35
NFKB2 Q00653 1/20 0.35
RELA Q04206 1/20 0.35
CBLB Q13191 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL479936 1.00 SMN1; SMN2 (0.36) SMN1; SMN2KDM4ELMNAALDH1A1GRM5
SCHEMBL480256 0.92 GRM5 (0.38) SMN1; SMN2LMNAALDH1A1GRM5KMT2A
SCHEMBL15789688 0.89 GRM5 (0.36) SMN1; SMN2LMNAALDH1A1GRM5KMT2A
SCHEMBL752907 0.87 BTK (0.38) SMN1; SMN2LMNAKMT2ABTKNPC1
SCHEMBL479868 0.87 BTK (0.38) SMN1; SMN2LMNAKMT2ABTKNPC1
SCHEMBL479734 0.86 MAPT (0.43) SMN1; SMN2LMNAKMT2ANPC1TP53
SCHEMBL753147 0.86 MAPT (0.43) SMN1; SMN2LMNAKMT2ANPC1TP53
SCHEMBL754346 0.85 NPC1 (0.52) SMN1; SMN2LMNAKMT2ANPC1NFKB1
SCHEMBL479607 0.85 NPC1 (0.52) SMN1; SMN2LMNAKMT2ANPC1NFKB1
SCHEMBL479782 0.85 HDAC1 (0.35) SMN1; SMN2LMNAGRM5KMT2ABTK

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2411361-B1 1,1,1-TRIFLUORO-2-HYDROXYPROPYL COMPOUNDS HOFFMANN LA ROCHE (CH) 2014-06-18 EP disclosed
US-8138189-B2 Substituted benzene compounds as modulators of the glucocorticoid receptor HOFFMAN-LA ROCHE INC. (US) 2012-03-20 US disclosed
US-8138189-B2 Substituted benzene compounds as modulators of the glucocorticoid receptor HOFFMAN-LA ROCHE INC. (US) 2012-03-20 US disclosed
US-20100249139-A1 1,1,1-TRIFLUORO-2-HYDROXYPROPYL COMPOUNDS HOFFMANN-LA ROCHE, INC. 2010-09-30 US disclosed
US-20100249139-A1 1,1,1-TRIFLUORO-2-HYDROXYPROPYL COMPOUNDS HOFFMANN-LA ROCHE, INC. 2010-09-30 US disclosed
WO-2010108902-A1 1,1,1-TRIFLUORO-2-HYDROXYPROPYL COMPOUNDS F. HOFFMANN-LA ROCHE AG (CH) 2010-09-30 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100249139-A1 1,1,1-TRIFLUORO-2-HYDROXYPROPYL COMPOUNDS NR3C1, NR3C2, CRHR1 SMN1; SMN2 4229/4885KDM4E 1499/4885LMNA 1995/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.